Table 1.

Cohort characteristics at diagnosis (n = 33).

Patient characteristic	N (%), mean ± SD (range)
Age (years)	64.8 ± 9.03 (range 42–86)
Race
•White •Black •Asian/South Asian •Other •Unknown	•2 (6%) •4 (12%) •24 (73%) •2 (6%) •1 (3%)
BMI (kg/m2)	29.8 ± 7.4 (range 18.6–52.7)
Charlson comorbidity index	8.7 ± 1.4 (range 6–12)
Ca-125 (U/mL) at diagnosis (n = 30)	626.1 ± 938.1 (range 18–4000)
Histology at diagnosis on biopsy
•Endometrioid •Serous •Clear cell •Carcinosarcoma •Mixed •Mullerian adenocarcinoma •Other	•5 (15%) •11 (33%) •1 (3%) •1 (3%) •3 (9%) •11 (33%) •1 (3%)
Presumed FIGO stage at diagnosis
•3C* •4A* •4B	•5 (15%) •1 (3%) •27 (82%)
Location of disease at diagnosis
•Upper abdomen/omentum •Carcinomatosis •Distant lymph nodes •Lung/pleural •Bone •Brain	•11 (33%) •15 (45% •9 (27%) •14 (42%) •5 (15%) •2 (6%)
Response to neoadjuvant chemotherapy (n = 33)
•Complete response •Partial response •Stable disease •Progressive disease •Missing information	•1 (3%) •25 (76%) •0 (0%) •4 (12%) •3 (9%)
Interval cytoreductive surgery (n = 33)
•Yes •No	•25 (76%) •8 (24%)

Table 1 Legend: SD = standard deviation, BMI = body mass index, FIGO = international federation of gynecology and obstetrics.

^*Four 3C patients and one 4A patient presumed to have ovarian cancer at diagnosis.